Company intelligence / Profile preview

Qi An

Huzhou, Zhejiang, Chinaqianbio.com ↗

Ownership: Private
Development stage: Other

Overview

QiAn Biotech is a clinical-stage biopharmaceutical company based in Huzhou, China, dedicated to the development of innovative vaccines and therapeutics. The company utilizes a proprietary mRNA technology platform and recombinant protein expertise to target high-burden infectious diseases and oncology. Its lead candidate, QA-B01, is an mRNA-based COVID-19 vaccine that has advanced into clinical trials. QiAn Biotech integrates advanced antigen design with optimized lipid nanoparticle (LNP) delivery systems to create effective and accessible immunization solutions. The company's broader pipeline includes programs for shingles, HPV, and respiratory syncytial virus, aiming to address significant unmet global health needs.

Therapeutic areas: Infectious Diseases
Modalities: mRNA-based drugsVaccineLipid nanoparticle delivery therapyRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Qi An.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qi An.